Vilnius-based biotech startup Biomatter has secured €16.2 million in a funding round led by Astanor. Existing investors UVC Partners, Inventure, and Metaplanet also participated. The company previously raised €6.5 million in a 2024 seed round and €500,000 in 2021.
Founded in 2018, Biomatter uses an AI-driven platform to design custom enzymes from scratch, rather than relying on natural sequences. The company has delivered over 50 custom enzymes to more than 25 enterprise clients, including AstraZeneca, BASF, and Sanofi, across Europe, the US, and Japan.
The new capital will fund a 2,000 square meter design-and-testing facility in Vilnius, scheduled to open in 2027. The company aims to reduce enzyme development cycles from weeks to days. Additionally, the funds will support the expansion of the commercial team and the company's presence in the US.
